Editas Medicine, Inc. (EDIT)
NASDAQ: EDIT · Real-Time Price · USD
2.880
-0.030 (-1.03%)
Nov 4, 2024, 4:00 PM EST - Market closed
Editas Medicine Stock Forecast
Stock Price Forecast
The 12 analysts with 12-month price forecasts for Editas Medicine stock have an average target of 10.17, with a low estimate of 3.00 and a high estimate of 15. The average target predicts an increase of 253.13% from the current stock price of 2.88.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for EDIT stock from 12 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '24 | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 5 | 5 |
| Buy | 2 | 1 | 1 | 1 | 0 | 1 |
| Hold | 6 | 6 | 6 | 6 | 7 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 11 | 11 | 11 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Evercore ISI Group | Evercore ISI Group | Hold Maintains $7 → $3 | Hold | Maintains | $7 → $3 | +4.17% | Oct 23, 2024 |
| Wells Fargo | Wells Fargo | Buy Maintains $27 → $9 | Buy | Maintains | $27 → $9 | +212.50% | Oct 23, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $20 → $12 | Strong Buy | Maintains | $20 → $12 | +316.67% | Oct 22, 2024 |
| RBC Capital | RBC Capital | Hold Reiterates $8 | Hold | Reiterates | $8 | +177.78% | Sep 19, 2024 |
| Jones Trading | Jones Trading | Strong Buy Initiates $13 | Strong Buy | Initiates | $13 | +351.39% | Sep 17, 2024 |
Financial Forecast
Revenue This Year
29.87M
from 78.12M
Decreased by -61.76%
Revenue Next Year
15.94M
from 29.87M
Decreased by -46.63%
EPS This Year
-2.98
from -2.02
EPS Next Year
-2.71
from -2.98
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 76.0M | 38.9M | 254.1M | ||
| Avg | 29.9M | 15.9M | 46.4M | ||
| Low | 2.9M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.7% | 30.0% | 1,493.9% | ||
| Avg | -61.8% | -46.6% | 190.9% | ||
| Low | -96.2% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.43 | -1.94 | -1.42 | ||
| Avg | -2.98 | -2.71 | -2.57 | ||
| Low | -3.32 | -3.67 | -4.37 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.